Abstract

Background Achieving minimum clinically effective doses offers major advantages in safety and efficiency.Purpose To evaluate mean dosage in rheumatoid arthritis (RA) patients treated with adalimumab (ADA), etanercept (ETN) and infliximab...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call